Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab
Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab
复制标题
DOI：
10.1093/neuonc/now086
复制
发表时间：
2016-12-01
期刊：
影响因子：
15.9
通讯作者：
Huang, Raymond Y.
中科院分区：
文献类型：
--
作者：
Chang, Ken;Zhang, Biqi;Huang, Raymond Y.
背景。贝伐单抗是一种抗血管内皮生长因子的人源抗体，被批准用于治疗复发性胶质母细胞瘤。有必要发现成像生物标志物，以帮助选择可能从贝伐单抗中获得最大生存益处的患者。该研究的目的是检查治疗前和治疗后的多模态MRI特征是否可以预测复发性胶质母细胞瘤患者接受贝伐单抗治疗的无进展生存期和总生存期（OS）。患者群体包括84名训练组患者和42名测试组患者，根据治疗前成像日期分开。从对比度增强的t1加权和流体衰减的反演恢复图像中分割出感兴趣的肿瘤体积，并用于导出体积、形状、纹理、参数和直方图特征。共使用2293个治疗前特征和9811个治疗后特征来生成模型。采用标准放射学评估标准，预测OS的风险比为3.38 （P< 0.001）。治疗前和治疗后特征预测OS的风险比为5.10 (P
Background. Bevacizumab is a humanized antibody against vascular endothelial growth factor approved for treatment of recurrent glioblastoma. There is a need to discover imaging biomarkers that can aid in the selection of patients who will likely derive the most survival benefit from bevacizumab.Methods. The aim of the study was to examine if pre- and posttherapy multimodal MRI features could predict progression-free survival and overall survival (OS) for patients with recurrent glioblastoma treated with bevacizumab. The patient population included 84 patients in a training cohort and 42 patients in a testing cohort, separated based on pretherapy imaging date. Tumor volumes of interest were segmented from contrast-enhanced T1-weighted and fluid attenuated inversion recovery images and were used to derive volumetric, shape, texture, parametric, and histogram features. A total of 2293 pretherapy and 9811 posttherapy features were used to generate the model.Results. Using standard radiographic assessment criteria, the hazard ratio for predicting OS was 3.38 (P< .001). The hazard ratios for pre- and posttherapy features predicting OS were 5.10 (P